Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction

Figure 2

Patient survival after 1, 5, and 10 years was 95.85%, 92.16%, and 90.43% in the alemtuzumab group versus 92.67%, 83.77%, and 62.25% for KTx recipients who received basiliximab; .